MedPath

Molecular vs Conventional Microbiologic Diagnosis for Infections in Lung Transplantation

Recruiting
Conditions
Lung Transplant Infection
Molecular Diagnostic
Bacterial Infections
Tracheobronchitis
Pneumonia
Interventions
Diagnostic Test: BioFire Pneumonia Panel Plus
Registration Number
NCT05960383
Lead Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Brief Summary

The goal of this prospective study is to compare rapid molecular technique BioFire Pneumonia Panel Filmarray and conventional culture-based methods in the microbiologic diagnosis on bronchoalveolar lavage of lung transplant patients.

The main questions it aims to answer are:

* determine the microbiological concordance between molecular diagnostic and conventional culture techniques on donor's bronchoalveolar lavage before lung transplantation

* determine the microbiological concordance between molecular diagnostic and conventional culture techniques on recipient's bronchoalveolar lavage, performed 72 hours after lung transplantation

* determine the microbiological concordance between molecular diagnostic and conventional culture techniques in detecting molecular resistance patterns

* determine the difference in time to microbiological results between molecular diagnostic and conventional culture techniques

* determine time to clinical decision based on molecular diagnostic techniques compared to conventional culture techniques

Detailed Description

Molecular assays that detect bacterial organisms by nucleic acid sequences rather than culture have the potential to improve time to diagnosis for lower respiratory tract infections. However, their performance characteristics are unknown in lung transplant recipients.

PNEUMOARRAY is a prospective study, including all patients aged \>18 years that undergo lung transplantation from September 2022, at IRCCS Fondazione Cà Granda Policlinico in Milan. Patients who do not meet inclusion criteria are excluded from this study.

A fibro-bronchoscopy (FBS) with bronchoalveolar lavage (BAL) is performed, according to clinical practice, both on lungs donor and recipient. Donor's BAL is collected before graft transplantation, while BAL on lung transplant recipient is performed 72 hours after transplantation. On each BAL sample, both of lung donor and recipient, molecular diagnostic and culture exam are performed.

The goal of this prospective study is to compare rapid molecular technique BioFire Pneumonia Panel Filamarray and conventional culture-based methods in the microbiological diagnosis on bronchoalveolar lavage of lung transplant patients.

The primary outcome is:

-determine the microbiological concordance between molecular diagnostic and conventional culture techniques on donor's bronchoalveolar lavage before lung transplantation

Secondary outcomes are:

* determine the microbiological concordance between molecular diagnostic and conventional culture techniques on recipient's bronchoalveolar lavage, performed 72 hours after lung transplantation

* determine the microbiological concordance between molecular diagnostic and conventional culture techniques in detecting molecular resistance patterns

* determine the difference in time to microbiological results between molecular diagnostic and conventional culture techniques

* determine time to clinical decision based on molecular diagnostic techniques compared to conventional culture techniques

Sample size for statistical significance includes 53 patients.

For the majority of bacteria and fungi, microbiological culture from BAL remains the gold standard for diagnosis, but cultures are limited by long turnaround time and decreased sensitivity in patients that have received empiric anti-infective therapy. In this setting, fast microbiological diagnosis may be crucial to begin targeted antimicrobial therapy/prophylaxis and identify genes encoding resistance, in order to administer targeted therapy and to reduce antimicrobial resistance.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
53
Inclusion Criteria
  • all patients aged >18 years that undergo lung transplantation from February 2023, at IRCCS Fondazione Cà Granda Policlinico in Milan and performed FBS+BAL
Exclusion Criteria
  • Patients who do not meet inclusion criteria are excluded from this study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Lung transplant patientsBioFire Pneumonia Panel Plus53 patients who receive lung transplant and undergo microbiologic assessment with BioFire Pneumonia Panel Plus and conventional culture
Primary Outcome Measures
NameTimeMethod
microbiological concordance on donor's BAL2023-2024

determine the microbiological concordance between molecular diagnostic and conventional culture techniques on donor's bronchoalveolar lavage before lung transplantation

Secondary Outcome Measures
NameTimeMethod
microbiological concordance on recipient's BAL2023-2024

determine the microbiological concordance between molecular diagnostic and conventional culture techniques on recipient's bronchoalveolar lavage, performed 72 hours after lung transplantation

determine time to clinical decision2023-2024

determine time to clinical decision based on molecular diagnostic techniques compared to conventional culture techniques

concordance in in detecting molecular resistance patterns2023-2024

determine the microbiological concordance between molecular diagnostic and conventional culture techniques in detecting molecular resistance patterns

difference in time to microbiological results2023-2024

determine the difference in time to microbiological results between molecular diagnostic and conventional culture techniques

Trial Locations

Locations (1)

Irccs Fondazione Ca' Granda Policlinico Di Milano

🇮🇹

Milano, Italy

© Copyright 2025. All Rights Reserved by MedPath